Loading clinical trials...
Loading clinical trials...
AN INTERVENTIONAL PHASE 2, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMBOCYTOPENIA
Conditions
Interventions
PF-06835375
Locations
31
United States
East Carolina University
Greenville, North Carolina, United States
Liverpool Hospital
Liverpool, New South Wales, Australia
South West Radiology
Liverpool, New South Wales, Australia
Slade Pharmacy
Mount Kuring-Gai, New South Wales, Australia
Calvary Mater Newcastle
Waratah, New South Wales, Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia
Start Date
February 2, 2022
Primary Completion Date
August 2, 2028
Completion Date
August 2, 2028
Last Updated
April 16, 2026
NCT07039422
NCT06888960
NCT06594146
NCT07421167
NCT07083739
NCT04278924
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions